Method of treating cancer using dithiocarbamate derivatives
AssigneeCharlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
InventorThomas Preston Kennedy
Life of this patent
Estimating the term…
Abstract
Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
Claims51
A method of treating cancer in human cells and for sensitizing tumors to conventional cancer chemotherapy by blocking the P-glycoprotein membrane toxin extrusion pump and for sensitizing AIDS patients to anti-retroviral therapy by blocking the P-glycoprotein membrane toxin extrusion pump comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
- 7
- wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups;
- M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium;
- and n is the valence of the alkali metal.
A method of reducing hypoxic or ischemic damage to the cardiovascular system of a human comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
- 8
- wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups;
- M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium;
- and n is the valence of the alkali metal.
A method of reducing hypoxic or ischemic damage to the cardiovascular system of a human comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
- 9
- wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups;
- M is an alkali metal selected from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium;
- An is a metal selected from the group consisting of titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold;
- n is the valence of the metal.
A method for treating asthma or arthritis in humans comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
- 10
- wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups;
- M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium;
- and n is the valence of the alkali metal.
A method for treating asthma or arthritis in humans comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
- 11
- wherein R2 and R3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups;
- M is an alkali metal selected from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium;
- An is a metal selected from the group consisting of titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold;
- n is the valence of the metal.
Dependencies are inferred from the claim text.